摘要
糖尿病肾病综合征(diabeticnephropathysyndrome,DNS)是一种非免疫因素介导的继发性肾病综合征。由于其发病为非免疫因素介导,此类患者应用激素治疗无效,导致其引起的水肿在治疗上更加依赖利尿剂。新型利尿剂托伐普坦是一种选择性血管加压素V2受体拮抗剂,其发挥作用不依赖于白蛋白,目前主要用于减轻肝硬化、心力衰竭、抗利尿激素分泌异常综合征等导致的水肿,还可用于常染色体显性多囊肾病的辅助治疗,但在DNS患者中的应用较少。本文通过分享应用托伐普坦治疗1例顽固性水肿的DNS患者的经过,探讨托伐普坦治疗DNS患者的效果、安全性及未来前景。
Diabetic nephropathy syndrome(DNS)is a secondary nephrotic syndrome mediated by nonimmune factors.Such patients become more dependent on diuretics for the treatment of their induced edema due to ineffectiveness of the hormone as the onset of their disease is nonimmune mediated.The novel diuretic tolvaptan,a selective vasopressin V2 receptor antagonist independent of albumin,is currently used primarily to reduce edema caused by cirrhosis,heart failure,and abnormal antidiuretic hormone secretion,and may also be used as an adjunctive therapy in autosomal dominant polycystic kidney disease,but is used less frequently in patients with DNS.In this article,we discuss the effectiveness,safety,and future prospects of tolvaptan in the treatment of patients with DNS by sharing the experience of a DNS patient with edema treated with tolvaptan.
作者
刘睿茜
杨阳
高金祥
Liu Ruixi;Yang Yang;Gao Jinxiang(General Practice Department,Binzhou Medical University Hospital,Binzhou 256613,China)
出处
《国际医药卫生导报》
2024年第7期1172-1176,共5页
International Medicine and Health Guidance News
